Selank Research Guide: Tuftsin Analog and Lab Studies

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), built from tuftsin — a naturally occurring immunoglobulin fragment — and extended with a stabilizing Pro-Gly-Pro tail. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the V.V. Zakusov Research Institute of Pharmacology, Selank has accumulated a distinctive published record spanning enkephalin enzyme chemistry, rodent behavior, gene-expression studies in brain and spleen, and immunomodulatory experiments.

That combination — a neuroactive peptide with an immune-system ancestor — is what makes Selank unusual among research peptides. Tuftsin was first studied for its effects on phagocytic immune cells, and Selank's literature never fully left that heritage behind: the same research groups that measured its effects on anxiety-related behavior in animal models also measured cytokine and inflammation-related gene expression. This guide reviews what Selank is, how it was designed, what the primary literature reports at the molecular level, and how researchers evaluate Selank research material in the laboratory. All findings below are described as published research only.

What Is Selank?

Selank is a heptapeptide: seven amino acids in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its first four residues reproduce tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide fragment of the human immunoglobulin G heavy chain first described for its immunostimulant activity. The final three residues, Pro-Gly-Pro, are a deliberate addition — the same stabilizing extension used in Semax — intended to slow enzymatic breakdown of the parent sequence. Selank is also indexed in the literature under the code name TP-7, and it is supplied for laboratory research as a lyophilized synthetic peptide.

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
• Structure: Tuftsin (Thr-Lys-Pro-Arg) plus a C-terminal Pro-Gly-Pro extension
• Molecular formula: C33H57N11O9
• Molecular weight: Approximately 751.9 g/mol
• CAS number: 129954-34-3
• Synonym in the literature: TP-7

Origin and Design: A Tuftsin Analog Built for Stability

Tuftsin itself was identified in the 1970s as a fragment released from immunoglobulin G that stimulated phagocytosis — an early example of a peptide linking the immune system to a defined molecular signal. Like most short native peptides, however, tuftsin is degraded quickly, which limits its value as an experimental tool. The Russian design program that produced Selank addressed that problem the same way it had addressed Semax: keep the biologically interesting core sequence, and protect its C-terminus with Pro-Gly-Pro, a tripeptide that resists several peptidases.

The resulting molecule was studied primarily as a neuroactive peptide, and most of its published record comes from the Institute of Molecular Genetics and the Zakusov Institute groups. Two context points matter for reading that record. First, it is a literature concentrated in one research tradition, with many papers in Russian-language journals and limited independent replication elsewhere. Second, the studies span very different systems — plasma enzyme assays, mouse behavior, rat brain gene expression, human cell cultures — so no single experiment defines the compound; the pattern across systems is the evidence.

Studied Mechanisms in the Published Literature

Enkephalin-degrading enzymes

The earliest mechanistic proposal for Selank concerned the enkephalins, endogenous opioid peptides whose signaling is limited by degrading enzymes collectively called enkephalinases. Zozulya and colleagues reported that plasma enkephalin half-life was shortened in patients with generalized anxiety disorder in their study, and that in vitro Selank inhibited enzymatic hydrolysis of plasma enkephalin more potently than the reference inhibitors bacitracin and puromycin in the same assay. The authors proposed enkephalinase inhibition as a possible mechanism behind the anxiolytic activity reported in the research literature:

Citation: Zozulya AA, et al. "The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity." Bulletin of Experimental Biology and Medicine. 2001. [PubMed PMID: 11550013]

A follow-up study in mice added an important qualification: the effect was strain-dependent. Sokolov and colleagues found that Selank increased leu-enkephalin half-life and produced an anxiolytic effect in the open-field test in BALB/c mice, with no such effect in C57Bl/6 mice — a reminder that genotype shapes peptide responses in animal models:

Citation: Sokolov OYu, et al. "Effects of Selank on Behavioral Reactions and Activities of Plasma Enkephalin-Degrading Enzymes in Mice with Different Phenotypes of Emotional and Stress Reactions." Bulletin of Experimental Biology and Medicine. 2002. [PubMed PMID: 12432865]

GABAergic gene expression

A second mechanistic thread is transcriptional. Volkova and colleagues measured expression of 84 neurotransmission-related genes in rat frontal cortex after Selank administration and found widespread changes — 45 genes at one hour and 22 at three hours — with an expression pattern that correlated positively with the pattern produced by GABA itself in the same experiment. The authors concluded that one possible molecular mechanism is allosteric modulation of the GABAergic system:

Citation: Volkova A, et al. "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission." Frontiers in Pharmacology. 2016. [PubMed PMID: 26924987]

BDNF expression in rat hippocampus

Inozemtseva and colleagues reported that Selank regulated expression of brain-derived neurotrophic factor (BDNF) in rat hippocampus in vivo, with hippocampal Bdnf messenger RNA and BDNF protein changing on different timescales after administration in that study. The finding is notable because it places Selank in the same neurotrophin conversation as its sister compound Semax, even though the two peptides were designed from unrelated parent molecules:

Citation: Inozemtseva LS, et al. "Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo." Doklady Biological Sciences. 2008. [PubMed PMID: 18841804]

Learning, memory, and serotonin metabolism in rats

Semenova and colleagues studied Selank in Wistar rats trained with food reward, and reported that administration during the consolidation phase activated serotonin metabolism in hypothalamus and caudal brain stem and increased memory-trace stability over thirty days in retention tests. The authors attributed the reported effect in this animal model to Selank's action on brain serotonin and its metabolite:

Citation: Semenova TP, et al. "Experimental Optimization of Learning and Memory Processes by Selank." Eksperimental'naia i Klinicheskaia Farmakologiia. 2010. [PubMed PMID: 20919548]

An earlier rat study reached a compatible conclusion from a different task: Kozlovskii and Danchev reported that Selank activated learning in a conditioned active avoidance paradigm, most clearly in animals with initially poor learning ability:

Citation: Kozlovskii II, Danchev ND. "The Optimizing Action of the Synthetic Peptide Selank on a Conditioned Active Avoidance Reflex in Rats." Neuroscience and Behavioral Physiology. 2003. [PubMed PMID: 14552529]

Immune and inflammation-related gene expression

True to its tuftsin ancestry, Selank also has an immunology literature. Kolomin and colleagues used real-time PCR in mouse spleen and found significant expression changes in 34 of 84 inflammation-related genes examined — chemokines, cytokines, and their receptors — including marked changes in Bcl6 and its associated regulatory genes. The authors concluded that the data confirm Selank's participation, in this animal model, in regulation of inflammatory processes through genomic expression:

Citation: Kolomin T, et al. "Expression of Inflammation-Related Genes in Mouse Spleen under Tuftsin Analog Selank." Regulatory Peptides. 2011. [PubMed PMID: 21609736]

Human-cell work points in a related direction. Uchakina and colleagues reported that Selank altered interleukin-6 gene expression in peripheral blood cell cultures and changed Th1/Th2 cytokine balance measures in patients studied with generalized anxiety disorder and neurasthenia, and suggested on that basis that Selank acts as an immunomodulator in the systems studied:

Citation: Uchakina ON, et al. "Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008. [PubMed PMID: 18577961]

The Russian clinical literature — context, not product claims

For completeness, Selank was also examined in a published Russian clinical study of patients with generalized anxiety disorder and neurasthenia, in which Zozulya and colleagues compared it with medazepam using standard rating scales and serum enkephalin measures, and reported comparable anxiolytic effects for the two compounds in that study population:

Citation: Zozulya AA, et al. "Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008. [PubMed PMID: 18454096]

That study is part of the compound's published history in Russia. It is reported here as literature context only: it does not change the research-use-only status of Selank supplied as a laboratory material, and no conclusion about any commercial product should be drawn from it.

Selank and Semax: Parallel Designs, Different Parents

Selank and Semax are the two clearest examples of one design strategy applied to two unrelated parent peptides. Both are heptapeptides from the Institute of Molecular Genetics, and both end in Pro-Gly-Pro. Semax begins from ACTH, a hormone fragment, and its literature centers on neurotrophins, ischemia, and copper chemistry. Selank begins from tuftsin, an immune fragment, and its literature centers on enkephalin enzymes, GABAergic transcription, and cytokine gene expression. Researchers comparing the two should read our Semax research guide alongside this one — and note that a combination product pairing the two exists in catalogs precisely because their research traditions are complementary, not because they are variants of one molecule.

Research Applications in the Lab

• Enkephalinase and peptide-degradation assays — Selank as a characterized inhibitor in plasma enkephalin hydrolysis systems, following the Zozulya assay designs.
• Neurotransmission gene-expression studies — frontal-cortex transcription panels for GABAergic and related genes in rodent models, following Volkova and colleagues.
• Inflammation-related gene-expression studies — spleen and immune-tissue PCR panels for chemokine and cytokine genes, following Kolomin and colleagues; see also our overview of peptides in neuroprotection research for adjacent models.
• Neurotrophin readouts — hippocampal BDNF expression as a comparative endpoint alongside Semax in rodent studies.
• Behavioral pharmacology models — rodent learning, memory-consolidation, and anxiety-related paradigms in which Selank's strain-dependent effects are themselves a variable of interest.
• Structure–stability research — tuftsin versus Selank comparisons isolating what the Pro-Gly-Pro extension changes in degradation kinetics.

Analytical and Quality Notes

Identity and purity for Selank rest on the standard pair of measurements: reversed-phase HPLC, which separates the main peak from related impurities and yields a purity percentage, and mass spectrometry, which confirms the molecular weight against the specified structure — approximately 751.9 Da for the free heptapeptide. Because Selank differs from its parent tuftsin only by the C-terminal Pro-Gly-Pro extension, mass confirmation is the check that distinguishes the stabilized analog from the shorter parent sequence and from deletion-sequence impurities that HPLC alone might not make obvious.

Researchers should inspect the underlying data, not just the headline number: the chromatogram itself, the observed mass against the expected mass, and a certificate of analysis specific to the batch in hand. Our guide to reading a peptide COA walks through these checks in detail.

Conclusion

Selank is a tuftsin analog whose Pro-Gly-Pro extension turned a short-lived immune fragment into a durable research tool, and whose literature unusually spans both neuroscience and immunology: enkephalin-degrading enzyme inhibition in plasma assays, GABAergic gene-expression changes in rat cortex, BDNF regulation in hippocampus, serotonin-linked effects on memory consolidation in rats, and broad inflammation-related gene-expression changes in mouse spleen. Its evidence base is real but concentrated — largely one research tradition, predominantly preclinical — and it should be cited on those terms.

Before laboratory use, verify that the material shows at least 99% purity by HPLC, that its identity is confirmed by mass spectrometry against the 751.9 Da heptapeptide structure, and that it is accompanied by a batch-specific certificate of analysis matching the lot supplied. NUPEPS supplies Selank 10MG as a research material with batch documentation available for review, so researchers can confirm identity and purity for the exact lot in hand before designing experiments around it.